Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis

详细信息    查看全文

• 作者：Yu-Cheng Wu ; Hsian-He Hsu ; Wei-Chou Chang ; Ho-Jui Tung ; Kai-Hsiung Ko…
• 关键词：Targeted therapy ; Tumour response assessment ; Response criteria ; Non ; small cell lung cancer ; Survival
• 刊名：European Radiology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：25
• 期：6
• 页码：1801-1813
• 全文大小：2,165 KB
• 参考文献：1.Shepherd FA, Rodrigues Pereira J et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-32View Article PubMed
  2.Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364:947-55View Article PubMed
  3.Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133-44View Article PubMed
  4.Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-95View Article PubMed
  5.Rosell R, Molina MA, Costa C et al (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17:1160-168View Article PubMed
  6.Schaake EE, Kappers I, Codrington HE et al (2012) Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol 30:2731-738View Article PubMed
  7.Lee HY, Lee KS, Ahn MJ et al (2011) New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 73:63-9View Article PubMed
  8.Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-55View Article PubMed
  9.Lin LI (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255-68View Article PubMed
  10.Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-10View Article PubMed
  11.Lavin PT (1981) An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 4:451-57PubMed
  12.Karrison TG, Maitland ML, Stadler WM, Ratain MJ (2001) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455-461View Article
  13.Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2013) Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. Urol Oncol 31:1283-291View Article PubMed
  14.Suzuki C, Blomqvist L, Sundin A et al (2012) The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 23:948-54View Article PubMed
  15.Jang KM, Kim SH, Lee SJ et al (2013) Added value of diffusion-weighted MR imaging in the diagnosis of ampullary carcinoma. Radiology 266:491-01View Article PubMed
  16.Somoye G, Harry V, Semple S et al (2012) Early diffusion weighted magnetic resonance imaging can predict survival in women with locally advanced cancer of the cervix treated with combined chemo-radiation. Eur Radiol 22:2319-327View Article PubMed
  17.Wang J, Wu N, Cham MD et al (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193:1090-096View Article PubMed
  18.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-16View Article PubMed
  19.Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer 45:228-47View Article PubMed
  20.Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment–pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447-56View Article PubMed
  21.Husband JE, Schwartz LH, Spencer J et al (2004) Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 90:2256-260PubMed Central PubMed
  22.Lee HY, Lee KS, Hwang HS et al (2010) Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J Radiol 11:618-26View Article PubMed Central PubMed
  23.Kim YN, Lee HY, Lee KS et al (2012) Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? Korean J Radiol 13:702-10View Article PubMed Central PubMed
  24.Tsujino K, Kawaguchi T, Kubo A et al (2009) Response rate is associated with prolonged survival i
• 作者单位：Yu-Cheng Wu (1)
  Hsian-He Hsu (1)
  Wei-Chou Chang (1)
  Ho-Jui Tung (2)
  Kai-Hsiung Ko (1)
  Yi-Chih Hsu (1)
  Tsai-Wang Huang (3)
  Ching-Liang Ho (4)
  Hung Chang (3)
  
  1. Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, 325, Section 2, Cheng-Gong Road, Nei-Hu, Taipei, 114, Taiwan, Republic of China
  2. Department of Healthcare Administration, Asia University, Taichung, Taiwan, Republic of China
  3. Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
  4. Division of hematology-oncology, Department of internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Imaging and Radiology
  Diagnostic Radiology
  Interventional Radiology
  Neuroradiology
  Ultrasound
  Internal Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1084

文摘

Objectives We aimed to determine whether initial tumour responses measured during short-term follow-up computed tomography (CT) examinations after baseline examinations would correlate with clinical outcomes in patients with non-small cell lung cancer (NSCLC) who received epidermal growth factor receptor (EGFR)-targeted therapy. Methods A total of 86 gefitinib-treated patients with advanced adenocarcinoma of the lung were retrospectively reviewed. All patients underwent baseline and short-term follow-up CT examinations. The new response criteria (NRC) by Lee et al. were used for the response evaluations. A Cox proportional hazards multiple regression model and Kaplan–Meier survival analyses were used to evaluate correlations between the initial tumour changes and progression-free and overall survival (PFS, OS). Results Better separation and smaller p values were observed for both PFS and OS when good and poor disease responses (as defined by NRC) were compared after excluding tumours with characteristic morphologies. Early tumour changes correlated with PFS in a size-dependent manner. Moreover, a stronger association was observed between size changes and PFS when characteristic morphology was also considered. Conclusions Initial changes in tumour size during short-term post-treatment CT examinations could act as a potential prognostic imaging surrogate for PFS in gefitinib-treated patients with advanced adenocarcinoma of the lung. Key points -Initial responses to gefitinib on computed tomography significantly correlate with clinical outcomes. -Regardless of morphology, size decrease greater than 30?% predicts prolonged progression-free and overall survival. -Combination of size and morphological changes yields prognostic independence regarding progression-free survival.